September 6, 2022 7:56am

Are we sleep-walking into “crunches” in cash utilization, platform priority and employment cut-backs? Some companies are!

Indications: 5 Positive Indications, 1 Negative Indication and 1 Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

More frequently right than consequentially wrong; there is VALUE out there. What I provide is an intelligence daily.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.58% or (+181 points), S&P futures are UP +0.53% (+20 points) and NASDAQ futures are UP +0.43% (+52 points) early in the pre-open – so far,


Stock futures rose Tuesday as traders aimed starts the holiday-shortened week,

European markets inched higher,

Asia-Pacific markets traded mostly higher.



Indexes fell on Friday to cap their third (3rd) straight weekly decline, after a solid August jobs report failed to ease fears that the Fed would keep aggressively hiking interest rates to fight inflation.

After rallying through the morning, the Dow erased a 370-point gain and finished the session lower by 337.98 points, or -1.07%; the S&P 500 fell 45.59 points or -1.07%, its lowest close since July while the Nasdaq declined -154.28 points -1.3%, recording a six (6) day losing streak.

In August, the Dow lost -3% and S&P dived -3.3% while the Nasdaq fell -4.2%.

During Monday’s labor day holiday-shortened week for U.S. investors;  European markets closed lower on Monday as investors weighed energy concerns following news that Russia’s state-owned Gazprom would halt gas supplies to Europe through its Nord Stream 1 pipeline.

Economic Data Docket: investors are keeping an ear to the TV about speeches from Fed presidents as well as a fresh rate hike decision from the ECB (European Central bank) due out later this week. August PMI services and ISM services data are also slated for today.


RegMed Investors’ (RMi) Wednesday’s closing bell: cell and gene therapy sector coverage ended August on a neutral note. Investors have been displaced as a factor in the cell and gene therapy sector by electronic and algorithmic trading” <August 31, 2022> …


Ebb and flow –

Q3/22 – September – 1 holiday, 1 positive and 1 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes

Q2/22 –

·         June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indications:

BioLife Solutions (BLFS) closed down -$0.41 to $23.31 after Thursday’s -$0.11 with a positive +$0.10 or +0.43% pre-open indication,

Caribou Biosciences (CRBU) closed down Friday -$0.68 to $9.85 after Thursday’s -$0.65 with a positive +$0.48 or +4.93% pre-open indication.

Fate Therapeutics (FATE) closed down -$0.31 to $26.72 after Thursday’s -$0.11 with a positive +$0.73 or +2.73% pre-open indication,

Intellia Therapeutics (NTLA) closed down -$3.96 to $56.01 after Thursday’s -$0.09 with a positive +0.89 or +1.59% pre-open indication,

Verve Therapeutics (VERV) closed down -$1.21 to $36.75 after Thursday’s -$1.40 with a positive +$0.22 or +0.60% pre-open indication,


Negative Indication:

Beam Therapeutics (BEAM) closed down -$2.90 to $52.68 after Thursday’s -$0.98 with a negative -$0.60 or -1.14% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat at 6.20 after Thursday’s $0.00, Wednesday’s $0.00 after Tuesday’s +$1.05 with 675 shares traded after last Monday’s -$1.75 with 17,027 shares traded <3-month average = 1,617>,

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities?



The BOTTOM LINE: I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

I try to keep it simple … and short!

August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.

The previous Tuesday (8/30) had a negative close, Wednesday (8/31) experienced closed neutral, Thursday (9/1) closed positive and Friday (9/2) closed negative with Monday (9/4) being a holiday.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash? Start by looking at cell and gene therapy companies trading below cash!” 

How many companies are LOSING the investment high ground? TOO MANY …!!!

Do investors have all the information (G-2 intelligence) they need to maintain a position or add or sell a new “situation”?

Sector’s fundamentals have NOT improved since the beginning of the year – they roll up, down and round.

Investors need to come to terms of the cell and gene therapy sector’s state of affairs and health as individual company’s actions cast doubts upon sentiment as reflected by August’s final accounting of positive and negative closes.

Companies NEED BETTER outreach to investors which means … NOT to enrich themselves at shareholder’s expense!

CEO salaries, spending the G&A are totally OUT-OF-WHACK; these are companies are in the development stage and will be for years without products in most cases not like the tech companies, who CEOs and management teams think they should be compared to for bi-weekly cash and “beanies”!

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

Also, investors can’t afford the outsized valuation price targets by I-Banks research and believe that CEOs are “accomplices” to over-estimating expectation and guidance in regard to valuation

The only thing investors are able to hang to at that point is HOPE – which is not a technical or fundamental indicator.  Keep your eyes on historical pricings that, haven’t responded to I-Bank research price targets.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.